Mangalam Drugs & Organics Limited (BOM:532637)
30.88
-0.75 (-2.37%)
At close: Oct 16, 2026
Mangalam Drugs & Organics Revenue
Mangalam Drugs & Organics had revenue of 571.19M INR in the quarter ending June 30, 2026, a decrease of -0.16%. This brings the company's revenue in the last twelve months to 2.32B, down -22.21% year-over-year. In the fiscal year ending March 31, 2026, Mangalam Drugs & Organics had annual revenue of 2.32B, down -26.90%. That makes Mangalam Drugs & Organics the 32,614th largest company in the world by revenue and 2,392nd in India.
Revenue (ttm)
2.32B
Revenue Growth
-22.21%
P/S Ratio
0.21
Revenue / Employee
7.27M
Employees
319
Market Cap
488.78M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 2.32B | -854.43M | -26.90% |
| Mar 31, 2025 | 3.18B | -497.78M | -13.55% |
| Mar 31, 2024 | 3.67B | -28.42M | -0.77% |
| Mar 31, 2023 | 3.70B | -806.66M | -17.89% |
| Mar 31, 2022 | 4.51B | 708.84M | 18.65% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Murae Organisor | 8.59B |
| Rajnish Wellness | 1.68B |
| JFL Life Sciences | 1.31B |
| ANG Lifesciences India | 835.87M |
| Sandu Pharmaceuticals | 696.24M |
| Onyx Biotec | 694.69M |
| Phaarmasia | 486.17M |
| Biofil Chemicals and Pharmaceuticals | 346.26M |